Day: May 11, 2022

Lighthouse Labs will leverage the round to grow its team, broaden the ecosystem of worlds it partners with and targets summer 2022 launch

MONTREAL, May 11, 2022 (GLOBE NEWSWIRE) — Lighthouse, the company building the open metaverse navigation engine, today announces that it has raised a US$7 million seed round co-led by Accel, BlockTower and Animoca Brands. The round includes participation from White Star Capital, Sparkle Ventures, Gemini Frontier Fund, The Graph core developers StreamingFast, Tiny VC and angels including Patricio Worthalter (founder, POAP), Ryan Selkis (founder, Messari), Alex Svanevik (founder, Nansen), Thibault Launay (founder, Exclusible) and other high profile Web3 investors.

On the back of a year that saw virtual worlds like The Sandbox, Decentraland and Otherside sell hundreds of millions of dollars’ worth of land and attract names such as Adidas, Tommy Hilfiger and Snoop Dogg, the metaverse has rapidly captured public interest. Many new worlds have emerged to empower creators and capitalize on a market opportunity estimated at US$680 billion by 2030 (Grand View Research). The ecosystem’s rapidly growing level of fragmentation is making discovery an increasingly daunting experience for users and creators, who are now left wondering which world to explore and build experiences into.

Founded by Jonathan Brun and Justine Massicotte, Lighthouse seeks to solve this problem by simplifying discovery and mobility across the spatial web. Its platform, which will launch this summer, will enable users to search for places, events, creators, experiences, and even friends across and within virtual worlds. Beyond search, Lighthouse will offer a portal where users will be able to see trending activities, build groups of friends to explore the metaverse, see where their NFTs are usable and follow the work of specific brands and creators. Prior to launching Lighthouse, Jonathan Brun was Entrepreneur in Residence in White Star Capital’s Digital Asset Fund while Justine Massicotte was in charge of the Query Suggest engine at Coveo, a publicly-traded enterprise search company with global operations.

“If you are curious about the metaverse and don’t know where to start, Lighthouse will be the place to go,“ says Jonathan Brun, co-founder and CEO of Lighthouse. “Right now, discovery in the metaverse feels more like gaming, where you need to jump from one game to the next to find things, than the internet, where you can access everything from a single entry point. By building Lighthouse, we take the view that siloed worlds will eventually merge to become closer to the web. We’ve all seen how much standards and principles of openness propelled our digital lives with the internet. We are confident that Web3 virtual worlds will unite behind our vision of making the open metaverse a searchable place.”

“Lighthouse has the exciting opportunity to build a part of the unifying infrastructure for the metaverse,” said Andrei Brasoveanu, Partner at Accel. “The power of the metaverse lies in making it discoverable to a broad range of users, creators, and brands. Jonathan and Justine have thought hard about the opportunity ahead and what it takes to enable everyone to immerse themselves in this increasingly fragmented virtual world. We’re looking forward to partnering with the Lighthouse team on this journey!”

To power its platform, Lighthouse partners directly with the worlds for which it provides search capabilities. “Web search engines like Google or Brave use crawlers to discover publicly available web pages. However, because of the heavy and dynamic nature of 3D interactive media, powering real-time search across and within virtual worlds requires direct data integration. The open metaverse is still early, which gives us the opportunity to work hand-in-hand with projects to deploy standards that will ensure that the spatial web forms a cohesive unit,” said Lighthouse’s co-founder and CTO, Justine Massicotte.

Yat Siu, the executive chairman and co-founder of Animoca Brands, commented: “As a long-time builder and supporter of the open metaverse, Animoca Brands is well aware of Lighthouse’s overall value proposition and in particular of the pain points that the company is working to solve. We believe that Jonathan and Justine have the right vision and expertise to execute and we look forward to providing our assistance as they expand the universe of worlds they partner with.”

“As users will be spawning with their Avatars identity into many parallel virtual worlds in the open metaverse, we believe a new standard for a navigation system allowing for both content discovery and socialization layers will be needed, to aggregate metadata that facilitates connecting with your friends and communities across them and exploring content from one to another,” said Sebastien Borget, COO & co-founder of The Sandbox. “Lighthouse’s vision just focuses on that and we are happy to be working closely with them at The Sandbox and look forward to continuing providing our support to make the future truly open, transparent and interoperable.”

The funding will be used to grow Lighthouse’s engineering and community teams, expand the universe of worlds it partners with and launch its platform in Summer 2022.

To stay up to date with Lighthouse, keep an eye on their Discord, Medium and follow them on Twitter.

About Lighthouse Labs
Lighthouse is an open metaverse navigation engine that enables the search for places, events, friends, creators, assets, and experiences across and within virtual worlds. Through its portal, Lighthouse empowers users to find trending activities, build groups of friends to explore the metaverse, see where their NFTs are usable and follow the work of specific brands and creators. Lighthouse powers its solution by directly integrating with the virtual worlds for which it provides searchability capabilities. For more information visit: https://www.lighthouselabs.xyz/

Lighthouse is currently looking to expand the universe of worlds it partners with. If you are building a virtual world and would like to collaborate, go to https://www.lighthouselabs.xyz/ to book an intro meeting with the Lighthouse team.

Media Contact
Cat Staffell
cat@serotonin.co

The vaping industry veterans hope to cause waves with water-based vaping technology

LONDON, May 11, 2022 (GLOBE NEWSWIRE) — Innokin Technology has announced the launch of a new arrival to their industry-leading lineup of vaporizers. Introducing Lota: Innokin’s all-new sub-brand pushing the boundaries of performance, reliability, and innovation within the entry-level vaping sector.

Innokin’s Lota is set to shake up the vaping space by combining Innokin’s decade plus of industry-leading innovation expertise with Aquios Labs: a new technology firm that enables water-based e-liquid.

The partnership offers Lota an innovative new technology and approach to closed vaping systems. Aquios Labs’ first generation of water-based vape juice, AQ30, supports 30% water content. Water-based vaping delivers smoother vapour and faster satisfaction compared to traditional vaping systems. The extra 30% water content of AQ30 also reduces the dehydrating qualities that typical vapour can cause. Additionally, water-based vapes operate at a lower temperature compared to their traditional counterparts, which allows for greatly increased chemical stability during the vaping process.

Water-based technology and e-liquids result in a vaping experience that no other device can replicate, with no leakage, enhanced flavour clarity and faster nicotine satisfaction. These strengths paired with Innokin’s manufacturing experience catapult Lota into the spotlight of the disposable vape sector.

Lota will initially launch with a portfolio of three water-based devices, each with their own position for specific global markets and consumer needs: the Lota Enviro, F600, and Prefilled Pod Kit.

The Lota Enviro is a disposable device with a clear mission to reduce the carbon footprint of typical disposable vapes. The Lota F600 is Lota’s flagship disposable vaporizer, targeted for TPD markets. Rounding off Lota’s launch is the Lota Prefilled Pod, a closed pod system with a rechargeable battery integrated with revolutionary Aquios water-based vaping technology.

Commenting on the launch, Innokin Technology Co-Founder George Xia said: “Innokin has always believed in embracing new technology. When first introduced to Aquios Labs, our product development team was impressed with the unique advantages of water-based vaping. Through this exciting partnership, Innokin is proud to launch the Lota brand, offering high performance water-based vaping in our continued quest of tobacco harm reduction across the globe.”

You can find out more about Lota at innokin.com.

For further information and enquiring about collaborating with Innokin, please contact marketing@innokin.com.

Related Images

Image 1

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Featured Image for Innokin Technology

VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) — Following SOLVE FSHD’s recent acclaimed launch, the organization is pleased to formally announce the appointment of Dr. Eva Chin as the Executive Director. SOLVE FSHD’s Founder, Chip Wilson, has personally committed USD100 million to find a cure for facioscapulohumeral muscular dystrophy (FSHD), a rare disease he was diagnosed with at the age of 32. As the inaugural Executive Director for SOLVE FSHD, Dr. Chin will be responsible for aligning the organization’s goals with the expertise of researchers, scientists and companies to promote and fund the discovery and development of new therapies for FSHD.

“Dr. Chin’s experience and specialization in rare neuromuscular diseases add immense value to our organization. We are excited to gain her expertise and guidance to achieve the organization’s goal of finding a cure for FSHD by December 2027,” says Chip Wilson, SOLVE FSHD Founder. He added, “Within just a few weeks of the organization’s launch, SOLVE FSHD has received a tremendous response to the call for qualified grant applications and new therapeutic technologies, which will be reviewed under Dr. Chin’s leadership. In addition, she has worked tirelessly to build strong industry alliances for SOLVE FSHD, closely assessed the exciting projects to fund and facilitated collaborative funding opportunities across the academic and industry sectors in FSHD research and drug development.”

Dr. Chin obtained her Ph.D. in Physiology from the University of Waterloo in Canada and completed post-doctoral training at the University of Sydney, Australia and U.T. Southwestern Medical Center in Dallas, focusing on intracellular calcium in muscle fatigue and transcriptional regulation of gene expression in muscle fibre type determination and muscle plasticity.

“I am honoured to join the Solve FSHD team, supporting Chip and the Wilson Family in our mission to improve the quality of life for those affected by rare neuromuscular diseases by funding qualified research projects and pre-clinical and clinical research that will accelerate finding a cure for FSHD,” says Dr. Eva Chin, Solve FSHD Executive Director.

Dr. Chin’s career has spanned the academic and pharmaceutical industries, with previous positions at Pfizer, the University of Maryland, MyoTherapeutics, Cytokinetics and NMD Pharma. While at Pfizer, Eva shifted her career from academic research focusing on cellular and molecular mechanisms of muscle function to discovering and developing muscle-targeted therapies. Over the past five years, she has led the nonclinical development of numerous drug candidates in clinical trials for ALS, SMA, myasthenia gravis and hypertrophic cardiomyopathy.

Under Dr. Chin’s guidance, Solve FSHD’s venture-philanthropic funding model will strategically utilize Wilson’s monetary commitment to support the initial grants, investments in early-stage companies focused on FSHD and to incentivize pharmaceutical companies in the neuromuscular disease space to increase their focus on FSHD. The venture philanthropy model will enable the organization to be financially self-sustainable through return on investments. The investments in viable, albeit high-risk, research opportunities may generate a continued re-investment stream into the organization to further support grant funding initiatives.

“To take advantage of recent advances in genetic therapeutics, SOLVE FSHD constructed a creative funding platform to facilitate the development of treatments that rapidly slow, stop or even reverse weakness in FSHD,” said Dr. John Day, MD, Ph.D., Director of Stanford University’s Neuromuscular Medicine program. “Having someone with Dr. Eva Chin’s experience and capabilities join SOLVE FSHD is critical to establishing the scientifically rigorous program needed to define and validate safe and effective treatments as quickly as possible,” says Dr. John Day, MD, Ph.D., Neuromuscular Medicine, Stanford Neuroscience Health Center.

About Solve FSHD
Solve FSHD is funding innovative biotech and biopharma research and development activities that accelerate novel treatments of Facioscapulohumeral muscular dystrophy (FSHD) treatment. It is fully funded and created by Canadian entrepreneur and philanthropist Chip Wilson. The founder of yoga-inspired athletic apparel company Lululemon Athletica inc. has been living with FSHD for the last three decades of his life. He has committed $100 million of his own money to create SOLVE FSHD and kick-start funding into projects that fit the organization’s mission: accelerate research into new therapies and find a cure for the disorder by 2027.

Future announcements for grant funding will be issued on SOLVE FSHD’s website – https://solvefshd.com/. For early-stage companies, contact SOLVE FSHD at info@solvefshd.com.

If you have FSHD and want to find out about clinical trials or be included in the FSHD registry, please see SOLVE FSHD’s website – https://solvefshd.com/

For media inquiries or to request a media interview, please contact:
Kamran Shaikh, Account Director
PR Associates
kshaikh@prassociates.com
778-846-5406

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0e87aacb-92f4-4723-9e7e-e24021cff5f7

SYDNEY, Australia, May 11, 2022 (GLOBE NEWSWIRE) — ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services. ENA Respiratory is the first Australian company to be selected to join Blue Knight.

Blue Knight offers a scientific and technological ecosystem for innovative, early-stage companies to develop strategically aligned technologies that aim to combat health threats and emerging infectious diseases. ENA Respiratory’s selection highlights the urgent unmet need for therapies that could help the body respond faster to a broad range of respiratory viral infections and reduce the risk of hospitalization or complications. As a Blue Knight company, ENA Respiratory will benefit from mentorship from experts from BARDA, the Johnson & Johnson Family of Companies, and a global network of innovators who could provide critical insight and support throughout INNA-051 development.

ENA Respiratory’s self-administered nasal spray INNA-051 product is designed with the aim to stimulate the innate immunity in the nose, which is the preferential site of initial infection and replication of most respiratory viruses. Pre-clinical research demonstrates that INNA-051 has pan-antiviral potential with efficacy against a variety of respiratory viruses, including SARS-CoV-2, influenza, and the common cold rhinovirus.

“As we continue to advance the development of INNA-051, we look forward to working alongside BARDA, industry leaders, and other innovative companies with the aim to address emerging health threats and better protect our global community against infectious diseases,” said Christophe Demaison, Ph.D., CEO of ENA Respiratory.

ENA Respiratory is a virtual resident within JLABS, a premier life science incubator program.

Recently, ENA Respiratory began a Phase 2a influenza challenge pre-exposure prophylaxis study of INNA-051. It was found to be well-tolerated in a Phase 1 study, and Phase 1 data will be presented at the 2022 American Thoracic Society International Conference (May 13- 18, San Francisco).

Notes to Editors

If you would like to arrange an interview, please contact:

• Glenn Silver, Finn Partners, +1 973 818 8198, glenn.silver@finnpartners.com

About ENA Respiratory and INNA-051

ENA Respiratory is aiming to transform the prevention of respiratory viral infections in populations at-risk of complications. The company is based in Melbourne and Sydney, Australia and it has secured a Series A funding from Brandon Capital Partners’ managed funds, the Minderoo Foundation, and Uniseed.

INNA-051 is a potent innate immune TLR2/6 agonist. It is being developed for intranasal delivery to target the preferential site of initial infection and replication of most respiratory viruses, including SARS-CoV-2 and influenza. Fast-acting and inducing a durable biologic response supporting weekly administration, INNA-051 works by recruiting innate immune cells and priming epithelial cells of the nasal mucosa to respond more quickly to infections, rapidly eliminating viruses and other pathogens before they spread throughout the body. INNA-051 and close analogues have been shown in preclinical studies to be effective against multiple respiratory viruses, including SARS-CoV-2, influenza (H1N1 and seasonal H3N2), and rhinovirus.

Key features of INNA-051 intranasal administration include limited minimal or no systemic bioavailability, minimal or no systemic pro-inflammatory cytokine release, no direct type I interferon upregulation which is known to be associated with fever in humans, durable immune response supporting weekly administration, and compatibility with vaccine and intranasal corticosteroids.

For more information, please visit https://enarespiratory.com

A glowing flower wins the annual competition to capture the art of science

WALTHAM, Mass., May 11, 2022 (GLOBE NEWSWIRE) — Evident, a new wholly owned subsidiary of Olympus comprised of its former Life Science and Industrial divisions, unveiled the winners of its third Global Image of the Year Life Science Light Microscopy Award, an annual competition that recognizes the best in life science imaging. The winners were selected from nearly 800 images submitted from 49 countries around the world.

Global Winner
Jan Martinek from the Czech Republic was selected as the global winner for a glowing image of an Arabidopsis thaliana flower with pollen tubes growing through the pistil. The flower tissues were chemically cleared to reveal the pollen tubes stained with aniline blue (yellow fluorescence). Martinek chose to image this flower to highlight the beauty of science in plant cell research.

“Plants are fascinating and beautiful on all levels of magnification, from the level of ecosystems to the level of individual cells,” Martinek explained. “As a plant cell biologist, I spend hours looking at plants under the microscope. I see a lot of beautiful images, like this flower of Arabidopsis thaliana with pollen tubes growing through the pistil to fertilize the ovules. However, I capture hundreds of pictures like this just to measure the lengths of the pollen tubes, and readers of my research articles will see only some boxplots comparing the pollination efficiency of different mutants. I share these pictures on my social media for fellow scientists and the general public to enjoy the beauty of science, which sometimes stays hidden behind the statistically significant results. I am happy that thanks to the IOTY Award, my and others’ pictures of this fascinating microcosm get worldwide attention.”

Martinek will receive the grand prize, an Olympus SZX7 stereo microscope with a DP28 digital camera.

Regional Winners
Three regional prizes were awarded to Vasilis Kokkoris (the Netherlands) for EMEA, Ivan Radin (USA) for the Americas and Daniel Han (Australia) for Asia. Each regional winner will receive an Olympus CX23 upright microscope.

Honorable Mentions
Honorable mentions include Di Lu (China), Yujun Chen (USA), Mingyue Jia (China), David Maitland (UK), Layra Cintron-Rivera (USA), Igor Siwanowicz (USA) and Yayun Wang (China).

The contest launched on Oct. 19, 2021, with a call for users to submit their best life science microscopy images through Jan. 31, 2022. All entries were evaluated on artistic and visual aspects, scientific impact and microscope proficiency.

From flowers to fungus and ferns, the Evident Life Science team was impressed by the fascinating specimens masterfully captured under the microscope.

“I continue to be amazed by the creative images we see each year that turn life under the microscope into unique art pieces,” said Satoshi Nakamura, Vice President of Scientific Solutions Global Marketing at Evident. “We are honored to receive so many stunning captures from around the world that visually blend artistic creativity and science. The winning images create a beautiful image gallery showcasing an incredible level of talent and technique at the microscope.”

About the Image of the Year (IOTY) Award
The IOTY Award began in 2017 as Olympus’ Image of the Year European Life Science Light Microscopy Award with the aim to celebrate both the artistic and scientific value of microscopy images. Today, as the Evident IOTY, the competition stays true to this mission by encouraging people around the world to look at scientific images in a new way, appreciate their beauty, and share images with others.

To learn more about the award-winning images and the microscope techniques used to capture them, visit Olympus-LifeScience.com/IOTY.

For more information about Evident Life Science, visit EvidentScientific.com.

About EVIDENT 
At Evident, we are guided by the scientific spirit—innovation and exploration are at the heart of what we do. Committed to making people’s lives healthier, safer and more fulfilling, we support our customers with solutions that solve their challenges and advance their work; whether it’s researching medical breakthroughs, inspecting infrastructure, or exposing hidden toxins in consumer products.

Evident Industrial’s solutions range from microscopes and videoscopes to nondestructive testing equipment and X-ray analyzers for maintenance, manufacturing and environmental applications. Backed by state-of-the-art technologies, Evident products are widely used for quality control, inspection, and measurement.

Evident Life Science empowers scientists and researchers through collaboration and cutting-edge life science solutions. Dedicated to meeting the challenges and supporting the evolving needs of its customers, Evident Life Science advances a comprehensive range of microscopes for pathology, hematology, IVF and other clinical applications as well as for research and education.

For more information, visit EvidentScientific.com.

Evident and the Evident logo are trademarks of Evident Corporation or its subsidiaries.

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/eb5960a2-538e-4373-8f99-f75be0a2e482

Media Contact:
Hilary Banda
781-419-3624
Hilary.Banda@EvidentScientific.com

New solution will allow businesses to aggregate and calculate life cycle assessments quickly and at scale

CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) — Sphera®, a leading global provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services, today announced the launch of its new Life Cycle Assessment (LCA) Automation software, building upon the company’s existing LCA solutions. The move comes as investor and regulatory pressures surrounding the standardization and digitalization of end-to-end sustainability data measurement continue to mount, necessitating increasingly sophisticated and granular reporting and compliance tools.

Sphera’s next-generation solution integrates seamlessly with customers’ existing systems for rapid deployment, allowing customers to quickly receive holistic, real-time analysis and insights into the environmental footprint of their product portfolios. It also features extensive managed content that enables customers to instantaneously calculate their carbon footprint at scale and model how adjustments to specific variables—such as leveraging a cleaner power source or altering production processes—may affect emissions outputs.

The LCA Automation solution serves as an extension of Sphera’s existing Product Sustainability capabilities which include life cycle assessment software and content. The service allows a company to increase the number of LCAs by a factor of 1,000, in turn enabling the experienced LCA professional to focus on analyzing and improving results, versus creating them.

The overarching goal of Sphera’s LCA Automation tool is to help businesses—especially those in sectors with complex supply chains, such as manufacturing, consumer goods, paints and chemicals—to more effectively reduce their greenhouse gas (GHG) emissions at every step of production, from design to disassembly. Improved forecasting will facilitate holistic corporate decisions with sustainability incorporated at each stage, allowing teams to proactively predict and control environmental impact.

Paul Marushka, Sphera’s CEO and president, says: “Historically, LCAs have been viewed as voluntary, ad-hoc add-ons to broader corporate sustainability efforts. However, with consumer awareness growing in-step with regulatory mandates to mitigate the effects of climate change, LCA Automation feeds into the highest needs of decarbonization. As recent moves from the EU, SEC and the latest IPCC report have shown, financial and reputational fallout from a failure to act are very much a ‘when’, not an ‘if’.”

Continues Marushka, “From helping engineers create more sustainable products to enabling procurement professionals to establish lower carbon emission supply chains, LCA Automation will transform decision-making, for the benefit of both businesses and our planet.”

About Sphera
Sphera is the leading provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services focusing on Environment, Health, Safety & Sustainability (EHS&S), Operational Risk Management and Product Stewardship. For more than 30 years, we have served over 3,000 customers and a million-plus users in 80 countries to help companies keep their people safe, their products sustainable and their operations productive. Learn more about Sphera at www.sphera.com. Follow Sphera on LinkedIn.

Contact Information:
Astrid Dickinson
sphera@aspectusgroup.com

ENZYCHEM LIFESCIENCES’ CHAIRMAN & CEO RECEIVES “TOP 100 INNOVATION CEO OF 2022 AWARD”.

LONDON, May 11, 2022 (GLOBE NEWSWIRE) — Ki Young Sohn is Chairman and CEO of Enzychem Lifesciences, a late-stage biotechnology company. With more than 30 years of experience in the life sciences and finance industry, Ki Young has previously led teams in various pharmaceutical settings to success. Most recently, he has led positive Phase 2 US results for Enzychem Lifesciences’ lead candidate, EC-18 in Chemoradiation-induced Oral Mucositis (CRIOM) and execution of the partnership with Zydus Cadila to manufacture and distribute the world’s first COVID-19 pDNA vaccine.

Founded in 1999, Enzychem Lifesciences is developing novel small molecule therapeutics to target fundamental pathways in inflammation, for patients with unmet needs. Based on more than two decades of research, Enzychem developed its leading candidate EC-18, an oral small molecule derived from Sika deer antler, which has shown to be active across a number of different indications.

In recognition of Ki Young Sohn’s invaluable contributions to the biopharmaceutical industry, and Enzychem Lifesciences’ focus on improving the lives of patients with cancer and inflammatory diseases, World Biz Magazine has awarded Mr. Sohn a position within the Top 30 of the global list of 100 distinguished honorees.

Ki Young Sohn was also interviewed in World Biz Magazine where he shared insights into Enzychem Lifesciences’ mission and factors driving the company’s rapid growth. Read the interview here.

“It is a great honor to receive World Biz Magazine’s ‘Top 100 Innovation CEO’ Award. Developing novel therapeutics to patients with unmet needs is at the heart of Enzychem’s mission and culture. We will continue to innovate and advance the development of our therapies for the patients,” said Ki Young Sohn, Chairman and CEO of Enzychem Lifesciences.

World Biz Magazine’s Top 100 Innovation CEO Awards celebrates business leaders across the globe that are making major strides in  their industries. It recognizes product, service, functional, strategic, and managerial innovation. It also recognizes individuals showing exceptional commercial insight and market integrity. Sustainability forms a key cornerstone of the awards and is an integral part of the selection criteria. Every year over 40,000 leaders are shortlisted and following a stringent evaluation process, only 100 winners are selected.

Mike Walters, Editor in Chief of World Biz Magazine: “We are pleased to announce Ki Young Sohn as a recipient of the Award. To be highlighted within the Top 30 of the 100 winners is a testament to the pivotal role of Enzychem Lifesciences under Ki Young Sohn’s leadership in focusing on patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases.  Aside from its innovation DNA and exciting growth, Enzychem Lifesciences is an ESG centric company, best exemplified by its commitment to making COVID-19 vaccination available in low-medium income countries across Latin America and Asia.”

World Biz Magazine is the leading global C-Suite business journal with a readership spanning 32 countries, WBM focuses on leadership, innovation, investment and social responsibility. worldbizmagazine.net

Enzychem Lifesciences (KOSDAQ: 183490) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic and inflammatory diseases. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis. Enzychem is headquartered in South Korea, with an office in the United States. enzychem.com

Press contact: John West, awards@worldbizmagazine.com

Related Images

Image 1: KI YOUNG SOHN, CEO OF ENZYCHEM

This content was issued through the press release distribution service at Newswire.com.

Attachment

• KI YOUNG SOHN, CEO OF ENZYCHEM